LANCET ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2237668, encodeId=e374223e668e4, content=期刊对投稿的要求非常高，审稿速度还可，平均审稿时间为3周左右，但录用比例较低，属于极难发表的期刊。 接受多种类型的稿件，包括原创研究、评论文章、病例报告等（转化研究的接受率较低，纯基础研究则不被接受） 总得来时该期刊竞争还是比较激烈的，适合有显著研究成果和高质量研究设计的作者投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822137, createdTime=Mon Nov 18 22:50:29 CST 2024, time=2024-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=824, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210797, encodeId=28052210e979f, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为41.6，整体还是不错的，在肿瘤领域仍然处于靠前的位置。 CA-A CANCER JOURNAL FOR CLINICIANS，503.1，这个靠一篇文章打天下的，不必考虑 Nature Reviews Clinical Oncology 81.3，主要发表综述，不考虑 ANNALS OF ONCOLOGY，56.7主要是综述 CANCER CELL 48.8，主要发表转化医学为主，当然从前两年开始，也发表一点临床试验的文章了。 JOURNAL OF CLINICAL ONCOLOGY， 42.1分，与LANCET ONCOLOGY基本一样，平起平坐。 再往下，Cancer Discovery，29.7，也是发表基础研究和转化医学研究的文章，与临床比较远。 Journal of Hematology & Oncology 29.5 这是血液肿瘤和实体瘤综合刊物，厉害 Molecular Cancer 27.7也是肿瘤转化医学相关的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:54:19 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2209164, encodeId=d69522091645f, content=8, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece95434233, createdName=ms1000000822606544, createdTime=Sun Jun 09 22:45:55 CST 2024, time=2024-06-09, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿，天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分，顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=438, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=922, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=706, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=720, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2024-11-18 ms1000001788822137 来自上海

期刊对投稿的要求非常高，审稿速度还可，平均审稿时间为3周左右，但录用比例较低，属于极难发表的期刊。
接受多种类型的稿件，包括原创研究、评论文章、病例报告等（转化研究的接受率较低，纯基础研究则不被接受）
总得来时该期刊竞争还是比较激烈的，适合有显著研究成果和高质量研究设计的作者投稿。

62 0

[GetPortalCommentsPageByObjectIdResponse(id=2237668, encodeId=e374223e668e4, content=期刊对投稿的要求非常高，审稿速度还可，平均审稿时间为3周左右，但录用比例较低，属于极难发表的期刊。 接受多种类型的稿件，包括原创研究、评论文章、病例报告等（转化研究的接受率较低，纯基础研究则不被接受） 总得来时该期刊竞争还是比较激烈的，适合有显著研究成果和高质量研究设计的作者投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822137, createdTime=Mon Nov 18 22:50:29 CST 2024, time=2024-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=824, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210797, encodeId=28052210e979f, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为41.6，整体还是不错的，在肿瘤领域仍然处于靠前的位置。 CA-A CANCER JOURNAL FOR CLINICIANS，503.1，这个靠一篇文章打天下的，不必考虑 Nature Reviews Clinical Oncology 81.3，主要发表综述，不考虑 ANNALS OF ONCOLOGY，56.7主要是综述 CANCER CELL 48.8，主要发表转化医学为主，当然从前两年开始，也发表一点临床试验的文章了。 JOURNAL OF CLINICAL ONCOLOGY， 42.1分，与LANCET ONCOLOGY基本一样，平起平坐。 再往下，Cancer Discovery，29.7，也是发表基础研究和转化医学研究的文章，与临床比较远。 Journal of Hematology & Oncology 29.5 这是血液肿瘤和实体瘤综合刊物，厉害 Molecular Cancer 27.7也是肿瘤转化医学相关的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:54:19 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2209164, encodeId=d69522091645f, content=8, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece95434233, createdName=ms1000000822606544, createdTime=Sun Jun 09 22:45:55 CST 2024, time=2024-06-09, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿，天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分，顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=438, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=922, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=706, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=720, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2019-01-01 sunliang

这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表:
是周彩存

153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存

824 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237668, encodeId=e374223e668e4, content=期刊对投稿的要求非常高，审稿速度还可，平均审稿时间为3周左右，但录用比例较低，属于极难发表的期刊。 接受多种类型的稿件，包括原创研究、评论文章、病例报告等（转化研究的接受率较低，纯基础研究则不被接受） 总得来时该期刊竞争还是比较激烈的，适合有显著研究成果和高质量研究设计的作者投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822137, createdTime=Mon Nov 18 22:50:29 CST 2024, time=2024-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=824, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210797, encodeId=28052210e979f, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为41.6，整体还是不错的，在肿瘤领域仍然处于靠前的位置。 CA-A CANCER JOURNAL FOR CLINICIANS，503.1，这个靠一篇文章打天下的，不必考虑 Nature Reviews Clinical Oncology 81.3，主要发表综述，不考虑 ANNALS OF ONCOLOGY，56.7主要是综述 CANCER CELL 48.8，主要发表转化医学为主，当然从前两年开始，也发表一点临床试验的文章了。 JOURNAL OF CLINICAL ONCOLOGY， 42.1分，与LANCET ONCOLOGY基本一样，平起平坐。 再往下，Cancer Discovery，29.7，也是发表基础研究和转化医学研究的文章，与临床比较远。 Journal of Hematology & Oncology 29.5 这是血液肿瘤和实体瘤综合刊物，厉害 Molecular Cancer 27.7也是肿瘤转化医学相关的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:54:19 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2209164, encodeId=d69522091645f, content=8, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece95434233, createdName=ms1000000822606544, createdTime=Sun Jun 09 22:45:55 CST 2024, time=2024-06-09, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿，天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分，顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=438, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=922, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=706, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=720, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2024-06-20 侠胆医心来自伊利诺伊

审稿速度:3.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤
经验分享：2023年度影响因子为41.6，整体还是不错的，在肿瘤领域仍然处于靠前的位置。
CA-A CANCER JOURNAL FOR CLINICIANS，503.1，这个靠一篇文章打天下的，不必考虑
Nature Reviews Clinical Oncology 81.3，主要发表综述，不考虑
ANNALS OF ONCOLOGY，56.7主要是综述
CANCER CELL 48.8，主要发表转化医学为主，当然从前两年开始，也发表一点临床试验的文章了。
JOURNAL OF CLINICAL ONCOLOGY， 42.1分，与LANCET ONCOLOGY基本一样，平起平坐。
再往下，Cancer Discovery，29.7，也是发表基础研究和转化医学研究的文章，与临床比较远。
Journal of Hematology & Oncology 29.5 这是血液肿瘤和实体瘤综合刊物，厉害
Molecular Cancer 27.7也是肿瘤转化医学相关的。

231 0

[GetPortalCommentsPageByObjectIdResponse(id=2237668, encodeId=e374223e668e4, content=期刊对投稿的要求非常高，审稿速度还可，平均审稿时间为3周左右，但录用比例较低，属于极难发表的期刊。 接受多种类型的稿件，包括原创研究、评论文章、病例报告等（转化研究的接受率较低，纯基础研究则不被接受） 总得来时该期刊竞争还是比较激烈的，适合有显著研究成果和高质量研究设计的作者投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822137, createdTime=Mon Nov 18 22:50:29 CST 2024, time=2024-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=824, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210797, encodeId=28052210e979f, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为41.6，整体还是不错的，在肿瘤领域仍然处于靠前的位置。 CA-A CANCER JOURNAL FOR CLINICIANS，503.1，这个靠一篇文章打天下的，不必考虑 Nature Reviews Clinical Oncology 81.3，主要发表综述，不考虑 ANNALS OF ONCOLOGY，56.7主要是综述 CANCER CELL 48.8，主要发表转化医学为主，当然从前两年开始，也发表一点临床试验的文章了。 JOURNAL OF CLINICAL ONCOLOGY， 42.1分，与LANCET ONCOLOGY基本一样，平起平坐。 再往下，Cancer Discovery，29.7，也是发表基础研究和转化医学研究的文章，与临床比较远。 Journal of Hematology & Oncology 29.5 这是血液肿瘤和实体瘤综合刊物，厉害 Molecular Cancer 27.7也是肿瘤转化医学相关的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:54:19 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2209164, encodeId=d69522091645f, content=8, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece95434233, createdName=ms1000000822606544, createdTime=Sun Jun 09 22:45:55 CST 2024, time=2024-06-09, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿，天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分，顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=438, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=922, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=706, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=720, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2024-06-09 ms1000000822606544 来自青海省

8

221 0

[GetPortalCommentsPageByObjectIdResponse(id=2237668, encodeId=e374223e668e4, content=期刊对投稿的要求非常高，审稿速度还可，平均审稿时间为3周左右，但录用比例较低，属于极难发表的期刊。 接受多种类型的稿件，包括原创研究、评论文章、病例报告等（转化研究的接受率较低，纯基础研究则不被接受） 总得来时该期刊竞争还是比较激烈的，适合有显著研究成果和高质量研究设计的作者投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822137, createdTime=Mon Nov 18 22:50:29 CST 2024, time=2024-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=824, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210797, encodeId=28052210e979f, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为41.6，整体还是不错的，在肿瘤领域仍然处于靠前的位置。 CA-A CANCER JOURNAL FOR CLINICIANS，503.1，这个靠一篇文章打天下的，不必考虑 Nature Reviews Clinical Oncology 81.3，主要发表综述，不考虑 ANNALS OF ONCOLOGY，56.7主要是综述 CANCER CELL 48.8，主要发表转化医学为主，当然从前两年开始，也发表一点临床试验的文章了。 JOURNAL OF CLINICAL ONCOLOGY， 42.1分，与LANCET ONCOLOGY基本一样，平起平坐。 再往下，Cancer Discovery，29.7，也是发表基础研究和转化医学研究的文章，与临床比较远。 Journal of Hematology & Oncology 29.5 这是血液肿瘤和实体瘤综合刊物，厉害 Molecular Cancer 27.7也是肿瘤转化医学相关的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:54:19 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2209164, encodeId=d69522091645f, content=8, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece95434233, createdName=ms1000000822606544, createdTime=Sun Jun 09 22:45:55 CST 2024, time=2024-06-09, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿，天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分，顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=438, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=922, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=706, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=720, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-05-27 4031828 来自河南省

投稿投稿，天天发愁

447 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237668, encodeId=e374223e668e4, content=期刊对投稿的要求非常高，审稿速度还可，平均审稿时间为3周左右，但录用比例较低，属于极难发表的期刊。 接受多种类型的稿件，包括原创研究、评论文章、病例报告等（转化研究的接受率较低，纯基础研究则不被接受） 总得来时该期刊竞争还是比较激烈的，适合有显著研究成果和高质量研究设计的作者投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822137, createdTime=Mon Nov 18 22:50:29 CST 2024, time=2024-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=824, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210797, encodeId=28052210e979f, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为41.6，整体还是不错的，在肿瘤领域仍然处于靠前的位置。 CA-A CANCER JOURNAL FOR CLINICIANS，503.1，这个靠一篇文章打天下的，不必考虑 Nature Reviews Clinical Oncology 81.3，主要发表综述，不考虑 ANNALS OF ONCOLOGY，56.7主要是综述 CANCER CELL 48.8，主要发表转化医学为主，当然从前两年开始，也发表一点临床试验的文章了。 JOURNAL OF CLINICAL ONCOLOGY， 42.1分，与LANCET ONCOLOGY基本一样，平起平坐。 再往下，Cancer Discovery，29.7，也是发表基础研究和转化医学研究的文章，与临床比较远。 Journal of Hematology & Oncology 29.5 这是血液肿瘤和实体瘤综合刊物，厉害 Molecular Cancer 27.7也是肿瘤转化医学相关的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:54:19 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2209164, encodeId=d69522091645f, content=8, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece95434233, createdName=ms1000000822606544, createdTime=Sun Jun 09 22:45:55 CST 2024, time=2024-06-09, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿，天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分，顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=438, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=922, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=706, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=720, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-06-29 侠胆医心来自香港

影响因子51.1分，顶刊

438 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237668, encodeId=e374223e668e4, content=期刊对投稿的要求非常高，审稿速度还可，平均审稿时间为3周左右，但录用比例较低，属于极难发表的期刊。 接受多种类型的稿件，包括原创研究、评论文章、病例报告等（转化研究的接受率较低，纯基础研究则不被接受） 总得来时该期刊竞争还是比较激烈的，适合有显著研究成果和高质量研究设计的作者投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822137, createdTime=Mon Nov 18 22:50:29 CST 2024, time=2024-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=824, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210797, encodeId=28052210e979f, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为41.6，整体还是不错的，在肿瘤领域仍然处于靠前的位置。 CA-A CANCER JOURNAL FOR CLINICIANS，503.1，这个靠一篇文章打天下的，不必考虑 Nature Reviews Clinical Oncology 81.3，主要发表综述，不考虑 ANNALS OF ONCOLOGY，56.7主要是综述 CANCER CELL 48.8，主要发表转化医学为主，当然从前两年开始，也发表一点临床试验的文章了。 JOURNAL OF CLINICAL ONCOLOGY， 42.1分，与LANCET ONCOLOGY基本一样，平起平坐。 再往下，Cancer Discovery，29.7，也是发表基础研究和转化医学研究的文章，与临床比较远。 Journal of Hematology & Oncology 29.5 这是血液肿瘤和实体瘤综合刊物，厉害 Molecular Cancer 27.7也是肿瘤转化医学相关的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:54:19 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2209164, encodeId=d69522091645f, content=8, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece95434233, createdName=ms1000000822606544, createdTime=Sun Jun 09 22:45:55 CST 2024, time=2024-06-09, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿，天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分，顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=438, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=922, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=706, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=720, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2014-07-30 丁丁

审稿速度:1.0 | 投稿命中率:25.0
经验分享：楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。

1187 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237668, encodeId=e374223e668e4, content=期刊对投稿的要求非常高，审稿速度还可，平均审稿时间为3周左右，但录用比例较低，属于极难发表的期刊。 接受多种类型的稿件，包括原创研究、评论文章、病例报告等（转化研究的接受率较低，纯基础研究则不被接受） 总得来时该期刊竞争还是比较激烈的，适合有显著研究成果和高质量研究设计的作者投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822137, createdTime=Mon Nov 18 22:50:29 CST 2024, time=2024-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=824, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210797, encodeId=28052210e979f, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为41.6，整体还是不错的，在肿瘤领域仍然处于靠前的位置。 CA-A CANCER JOURNAL FOR CLINICIANS，503.1，这个靠一篇文章打天下的，不必考虑 Nature Reviews Clinical Oncology 81.3，主要发表综述，不考虑 ANNALS OF ONCOLOGY，56.7主要是综述 CANCER CELL 48.8，主要发表转化医学为主，当然从前两年开始，也发表一点临床试验的文章了。 JOURNAL OF CLINICAL ONCOLOGY， 42.1分，与LANCET ONCOLOGY基本一样，平起平坐。 再往下，Cancer Discovery，29.7，也是发表基础研究和转化医学研究的文章，与临床比较远。 Journal of Hematology & Oncology 29.5 这是血液肿瘤和实体瘤综合刊物，厉害 Molecular Cancer 27.7也是肿瘤转化医学相关的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:54:19 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2209164, encodeId=d69522091645f, content=8, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece95434233, createdName=ms1000000822606544, createdTime=Sun Jun 09 22:45:55 CST 2024, time=2024-06-09, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿，天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分，顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=438, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=922, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=706, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=720, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2019-11-17 1e2321c7m65(暂无匿称)

接受回顾性队列研究吗？

922 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237668, encodeId=e374223e668e4, content=期刊对投稿的要求非常高，审稿速度还可，平均审稿时间为3周左右，但录用比例较低，属于极难发表的期刊。 接受多种类型的稿件，包括原创研究、评论文章、病例报告等（转化研究的接受率较低，纯基础研究则不被接受） 总得来时该期刊竞争还是比较激烈的，适合有显著研究成果和高质量研究设计的作者投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822137, createdTime=Mon Nov 18 22:50:29 CST 2024, time=2024-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=824, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210797, encodeId=28052210e979f, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为41.6，整体还是不错的，在肿瘤领域仍然处于靠前的位置。 CA-A CANCER JOURNAL FOR CLINICIANS，503.1，这个靠一篇文章打天下的，不必考虑 Nature Reviews Clinical Oncology 81.3，主要发表综述，不考虑 ANNALS OF ONCOLOGY，56.7主要是综述 CANCER CELL 48.8，主要发表转化医学为主，当然从前两年开始，也发表一点临床试验的文章了。 JOURNAL OF CLINICAL ONCOLOGY， 42.1分，与LANCET ONCOLOGY基本一样，平起平坐。 再往下，Cancer Discovery，29.7，也是发表基础研究和转化医学研究的文章，与临床比较远。 Journal of Hematology & Oncology 29.5 这是血液肿瘤和实体瘤综合刊物，厉害 Molecular Cancer 27.7也是肿瘤转化医学相关的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:54:19 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2209164, encodeId=d69522091645f, content=8, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece95434233, createdName=ms1000000822606544, createdTime=Sun Jun 09 22:45:55 CST 2024, time=2024-06-09, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿，天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分，顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=438, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=922, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=706, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=720, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-12-29 Mia

我为什么投了一个月/很长时间都没有消息？

706 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237668, encodeId=e374223e668e4, content=期刊对投稿的要求非常高，审稿速度还可，平均审稿时间为3周左右，但录用比例较低，属于极难发表的期刊。 接受多种类型的稿件，包括原创研究、评论文章、病例报告等（转化研究的接受率较低，纯基础研究则不被接受） 总得来时该期刊竞争还是比较激烈的，适合有显著研究成果和高质量研究设计的作者投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822137, createdTime=Mon Nov 18 22:50:29 CST 2024, time=2024-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=824, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210797, encodeId=28052210e979f, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为41.6，整体还是不错的，在肿瘤领域仍然处于靠前的位置。 CA-A CANCER JOURNAL FOR CLINICIANS，503.1，这个靠一篇文章打天下的，不必考虑 Nature Reviews Clinical Oncology 81.3，主要发表综述，不考虑 ANNALS OF ONCOLOGY，56.7主要是综述 CANCER CELL 48.8，主要发表转化医学为主，当然从前两年开始，也发表一点临床试验的文章了。 JOURNAL OF CLINICAL ONCOLOGY， 42.1分，与LANCET ONCOLOGY基本一样，平起平坐。 再往下，Cancer Discovery，29.7，也是发表基础研究和转化医学研究的文章，与临床比较远。 Journal of Hematology & Oncology 29.5 这是血液肿瘤和实体瘤综合刊物，厉害 Molecular Cancer 27.7也是肿瘤转化医学相关的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:54:19 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2209164, encodeId=d69522091645f, content=8, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece95434233, createdName=ms1000000822606544, createdTime=Sun Jun 09 22:45:55 CST 2024, time=2024-06-09, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿，天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分，顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=438, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=922, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=706, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=720, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-12-28 桑晒麦拉

期刊的审稿时间一般是多久？

720 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务